Overview

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

Status:
Completed

Trial end date:
2017-11-28

Target enrollment:
0

Participant gender:
All

Summary

The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Antibodies
Antibodies, Monoclonal
Bevacizumab
Everolimus
Sirolimus

Criteria

Inclusion Criteria:

1. Patients with advanced or metastatic cancer that is refractory to standard therapy,
relapsed after standard therapy, or have no standard therapy that induces a CR rate of
at least 10% or improves survival by at least three months.

2. Patients should be at least four weeks from the last day of therapeutic radiation or
cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from
non-cytotoxic targeted or biologic therapy. Patients may have received palliative
radiation immediately before (or during) treatment provided radiation is not to the
only target lesion available.

3. ECOG performance status /= 60%).

4. Patients must have allowable organ and marrow function defined as: absolute neutrophil
count >/= 1,000/mL; platelets >/=50,000/mL; creatinine more than 350mg/dL; triglyceride level of no more than 400mg/dL.

5. Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study participation, and for 90 days after the last dose.

6. Ability to understand and the willingness to sign a written informed consent document

7. Patients may not be receiving any other investigational agents and/or any other
concurrent anticancer agents or therapies.

Exclusion Criteria:

1. Patients with hemoptysis within 28 days prior to entering the study.

2. Patients with clinically significant unexplained bleeding within 28 days prior to
entering the study

3. Uncontrolled systemic vascular hypertension (Systolic blood pressure > 140 mmHg,
diastolic blood pressure > 90 mmHg on medication).

4. Patients with clinically significant cardiovascular disease: - History of CVA within 6
months - Myocardial infarction or unstable angina within 6 months - Unstable angina
pectoris

5. Pregnant or lactating women.

6. History of hypersensitivity to bevacizumab, murine products, or any component of the
formulation.

7. History of hypersensitivity to Temsirolimus or its metabolites (including sirolimus),
polysorbate 80, or to any component of the formulation

8. Patients that are taking CYP3A4 inducers and/or inhibitors. Please see section 3.2 in
the protocol for details. If a patient has a history of taking CYP3A4 inducers and/or
inhibitors prior to enrollment on the protocol, it is strongly recommended that the
patient stops the drug and waits at least 5 half-lives of said drug before initiating
therapy on protocol.